Clinical efficacy and safety of bilastine. Part I Review article

Article Sidebar

PDF (Język Polski)


Published: Jan 4, 2023
DOI: https://doi.org/10.24292/01.AP.184040123
Keywords:
bilastine, efficacy, safety, allergic rhinitis

Main Article Content

Adam J. Sybilski
1. II Klinika Pediatrii, Centrum Medyczne Kształcenia Podyplomowego w Warszawie. 2. Klinika Chorób Dziecięcych i Noworodkowych z Centrum Alergologii i Dermatologii, Centralny Szpital Kliniczny MSWiA w Warszawie
http://orcid.org/0000-0003-2389-277X

Abstract

Histamine is the most important mediator of an allergic reaction. Its function is revealed by acting on H1 receptor. As a result of antigen–antibody reaction, histamine is released from mastocytes and stimulates H1 receptors. This reaction largely determines symptoms of allergic rhinitis, urticaria, food allergy, asthma and atopic dermatitis. The key role of histamine in the development of an allergic reaction causes H1 blockers (antihistamines) are the primary medications for the treatment of allergic diseases. The mechanism of action of antihistamines is based on their competitive and reversible association with H1 receptors, which reduces the action of histamine as an inflammatory mediator.


Bilastine is a second generation H1 antihistamine and has antihistamine and antiallergic properties. It has a high specificity for H1 receptors and negligible affinity for other receptors (H2, H3, H4). Bilastine has a rapid onset of action and a long duration of action.


The presented study presents meta-analyses evaluating the efficacy and safety of bilastine. Statistically significant reduction of allergic rhinitis and conjunctivitis symptoms and improvement of quality of life were demonstrated. Bilastine as an effective and safe second-generation antihistamine plays an important role in the treatment of allergic diseases. It is recommended and registered for the treatment of allergic rhinitis.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sybilski , A. J. (2023). Clinical efficacy and safety of bilastine. Part I. Alergoprofil, 18(4), 11-16. https://doi.org/10.24292/01.AP.184040123
Issue
Vol 18 No 4 (2022)
Section
THERAPY

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Pawankar R, Canonica GW, Holgate ST et al. World Allergy Organization (WAO) white book on allergy: update 2013. Milwaukee, USA: World Allergy Organization 2013; 11-13: 27-31, 60-63.
2. Sybilski AJ, Samoliński B. Leki przeciwhistaminowe. In: Emeryk A (ed). Alergiczny nieżyt nosa u dzieci. Termedia, Poznań 2011: 182-96.
3. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004; 351: 2203-17.
4. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008; 1: 145-55.
5. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy. 2009; 39: 1786-800.
6. Jutel M. Działanie sedacyjne leków przeciwhistaminowych. Alergia. 2007; 1: 9-11.
7. Coimbra J, Campo C, Labeaga L et al. Lack of clinical relevance of bilastine-food pharmacokinetic interaction assessed by inhibition of histamine-induced wheal and flare response in healthy volunteers. Skin Allergy Meeting 2019 April 4–6; Munich, Germany.
8. Church MK, Tiongco-Recto M, Ridolo E et al. Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2020; 36(3): 445-54.
9. Abdelshafy AM, Abdallah SY, Hassan AF et al. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Rhinol Allergy. 2022; 36(5): 684-94.
10. Okubo K, Gotoh M, Togawa M et al. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: results of an open-label trial. Auris Nasus Larynx. 2017; 44(3): 294-301.
11. Leceta A, García A, Sologuren A et al. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions. Drugs Context. 2021; 10: 2021-5-1.
12. Lynde CW, Sussman G, Dion PL et al. Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine. J Drugs Dermatol. 2020; 19(2): 145-54.
13. Singh Randhawa A, Mohd Noor N, Md Daud MK et al. Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis. Front Pharmacol. 2022; 12: 731201.
14. Jáuregui I, Ramaekers JG, Yanai K et al. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. Expert Opin Drug Saf. 2016; 15: 89-98.
15. Demonte A, Guanti MB, Liberati S et al. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients. Eur Rev Med Pharmacol Sci. 2018; 22(3): 820-8.